



**IN THE COMPETITION  
APPEAL TRIBUNAL**

Case Nos: 1432/1/12/22  
1434/1/12/22  
1438/1/12/22  
1439/1/12/22

BETWEEN:

- (1) ADVANZ PHARMA CORP. LIMITED & OTHERS  
(2) CINVEN CAPITAL MANAGEMENT (V) GENERAL PARTNER LIMITED &  
OTHERS  
(3) LEXON (UK) LIMITED & ANOTHER  
(4) ALLIANCE PHARMACEUTICALS LIMITED & ANOTHER**

Appellants

- v -

**COMPETITION AND MARKETS AUTHORITY**

Respondent

**AND IN THE MATTER OF LEXON UK HOLDINGS LIMITED, ALLIANCE  
PHARMACEUTICALS LIMITED, FOCUS PHARMACEUTICALS LIMITED,  
MERCURY PHARMA GROUP LIMITED, CONCORDIA INVESTMENT HOLDINGS  
(UK) LIMITED AND MEDREICH PLC AND OTHERS**

**AND IN THE MATTER OF THE COMPANY DIRECTORS DISQUALIFICATION  
ACT 1986**

BETWEEN:

**COMPETITION AND MARKETS AUTHORITY**

Claimant

-v-

- (1) PRITESH SONPAL; (2) PETER BUTTERFIELD; (3) JOHN DAWSON; (4) MARK  
CRESSWELL; (5) ROLAND BROWN; (6) GRAEME DUNCAN; (7) DEBANGSHU  
DEY**

Defendants

---

**ORDER**

---

**UPON** the letter from the Tribunal dated 14 March 2023 regarding the re-listing of the Pre-Trial Review for 15 May 2023 with a time estimate of one day (“the Tribunal Letter”)

**AND UPON** receiving no objections from the parties by the deadline specified in the Tribunal Letter

**IT IS ORDERED THAT:**

1. Paragraph 6 of the Order made and drawn on 14 November 2022 is varied such that there shall be a Pre-Trial Review on Thursday 18 May 2023 (with a time estimate of one day).

**The Honourable Lord Ericht**  
Chair of the Competition Appeal Tribunal

Made: 22 March 2023  
Drawn: 22 March 2023